FLT3 and synovial sarcoma: Here, we report a case of Sweet’s syndrome (SS) associated with gilteritinib that improved with cessation and reoccurred with rechallenge of this and quizartinib, providing a clearer link between this neutrophilic dermatosis and FLT3 inhibition.